AVIR - Atea Pharmaceuticals Inc Year-over-year net earnings per share growth for the last 12 months

Atea Pharma (AVIR) - corporate logo

Atea Pharmaceuticals (AVIR) is depleting its financial reserves on costly research, competing with global behemoths regarding the efficacy of its antiviral molecules. The percentage change in quarterly EPS demonstrates that the parameter reaches 24.60. Meanwhile, the absence of a stable cash flow leaves the company dependent on existing capital until the final drug trials are completed.

ateapharma.com (AVIR) Year-over-year net earnings per share change for the last twelve months: for the period 07/04/2022 - 11/14/2026

Atea Pharmaceuticals - analytical breakdowns and key metrics (AVIR)

- market value and analyst target forecast:
Price Chart Atea Pharmaceuticals Inc|AVIR - Fair Value Consensus
- market capitalization statistics:
Market Valuation Atea Corp|AVIR - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share Atea Pharmaceuticals|AVIR - Book Valuation of Business|Market Capitalization to Book Value Ratio ateapharma.com|AVIR - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio Atea Pharmaceuticals|AVIR - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Atea Corp|AVIR - Company Cumulative Debt|Debts to Book Capitalization Atea Corp|AVIR - Company Long-Term Debts|Company Current Liabilities Atea Pharmaceuticals|Quick Liquidity ateapharma.com
- earnings and market multiples details:
AVIR - Profit After Tax|Projected Future Earnings Atea Pharmaceuticals|AVIR - Company Value to Net Income|Forward P/E Multiple Atea Corp|AVIR - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Atea Pharmaceuticals, Inc.|AVIR - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Atea Pharmaceuticals|AVIR - Net earnings per share for the last 12 months|Quarterly EPS earnings growth ateapharma.com|AVIR - Earnings growth in current year|Earnings growth forecast for next year Atea Pharmaceuticals
- sales and revenue data:
AVIR - Company Sales|Projected Sales Volume ateapharma.com|AVIR - Price to Sales|Forward Price-to-Revenue Multiple Atea Corp
Comprehensive company analysis:Atea Pharma - AVIR
Finished products of Atea Corp

For the antiviral ecosystem of Atea Pharmaceuticals (AVIR), quarterly EPS growth serves as an indicator of R&D cycle efficiency. This metric measures the percentage change in net income per share relative to the same period last year. Positive momentum confirms the monetization of developments, while a decline signals rising clinical trial costs. For the investor, this trend determines the real cost of capital. Ignoring profit decay risks the purchase of an overvalued asset.

Competitor analysis

Gilead Sciences Inc (GILD) - Year-over-year earnings per share growth for the last twelve months|Cidara - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months NVAX|Quarterly EPS earnings growth curevac.com|Year-over-year earnings per share growth for the last twelve months Valneva Corp (VALN)|Year-over-year earnings per share growth for the last twelve months VIR (Vir Biotechnology)|Year-over-year earnings per share growth for the last twelve months TPOXX SIGA|EBS - Year-over-year net earnings per share growth for the last 12 months|IVVD - Year-over-year earnings per share growth for the last twelve months|ENTA (Enanta Pharmaceuticals) - Year-over-year earnings per share growth for the last 12 months|INO (Inovio) - Year-over-year net earnings per share growth for the last 12 months|HLVX (HilleVax Inc) - Year-over-year earnings per share growth for the last twelve months|KLRS (Kalaris Therapeutics Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months DYAI (Dyadic International)|Year-over-year net earnings per share growth for the last 12 months NNVC (NanoViricides)|TLPH (Talphera, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Cocrystal Pharma Inc COCP|Year-over-year earnings per one share growth for the last 12 months TRAW|Dogwood Therapeutics Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Qualigen Corp|ALVR (AlloVir Bio) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months VBI Vaccines, Inc.|VIRI (virios.com) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months VXRT (Vaxart, Inc.)